Lucile Packard Children's Hospital

Running trials

• Not yet recruiting

  Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia

  NCT07430254· Stanford University· Source

• Recruiting

  A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  NCT07306832· Phase 1· AbbVie· Source

• Enrolling by invitation

  Virtual Reality-enhanced Psychotherapy for Perinatal Depression

  NCT07279311· Stanford University· Source

• Recruiting

  Intraoperative Wound Irrigation for Pilonidal Disease

  NCT07417202· Stanford University· Source

• Recruiting

  Stanford Pediatric Healthy Weight Index

  NCT07316816· Stanford University· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

  NCT07087002· Phase 1· Stanford University· Source

• Recruiting

  Stanford Program to Accelerate Robotic Children's Surgery

  NCT06671639· Stanford University· Source

• Recruiting

  A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

  NCT07700966· Abeona Therapeutics, Inc· Source

• Active, not recruiting

  A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

  NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

  NCT06986382· Phase 1/2· Stanford University· Source

• Recruiting

  Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

  NCT06909110· Phase 1/2· Jessie L. Alexander· Source

• Recruiting

  Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

  NCT06080074· Phase 2· Stanford University· Source

• Recruiting

  A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

  NCT06423573· Chiesi Farmaceutici S.p.A.· Source

• Active, not recruiting

  A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

  NCT06413706· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  NCT06332534· Phase 3· AbbVie· Source

• Enrolling by invitation

  4T Sustainability Program

  NCT06314048· Stanford University· Source

• Recruiting

  Cord Clamping Among Neonates With Congenital Heart Disease

  NCT06153459· Carl Backes, MD· Source

• Active, not recruiting

  Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

  NCT05782907· Phase 3· AbbVie· Source

• Recruiting

  Precise Infliximab Exposure and Pharmacodynamic Control

  NCT05660746· Phase 2/3· Children's Hospital Medical Center, Cincinnati· Source

• Active, not recruiting

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05881408· Phase 3· Sarepta Therapeutics, Inc.· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  NCT05714085· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

  NCT05734066· Phase 1/2· Jazz Pharmaceuticals· Source

• Recruiting

  Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

  NCT05508009· Phase 1/2· Alice Bertaina· Source

• Enrolling by invitation

  EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

  NCT05610787· Berlin Heart, Inc· Source

• Active, not recruiting

  Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

  NCT05206357· Phase 1· Genmab· Source

• Recruiting

  A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

  NCT05265273· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

  NCT05076175· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

  NCT04819841· Phase 1/2· Kamau Therapeutics· Source

• Active, not recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

  NCT04774718· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback

  NCT04640987· Phase 1· Porteus, Matthew, MD· Source

• Enrolling by invitation

  A Long-term Follow-up Study in Participants Who Received CTX001

  NCT04208529· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

  NCT04142437· Bayer· Source

• Recruiting

  Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

  NCT04278404· Duke University· Source

• Active, not recruiting

  Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

  NCT03478462· Phase 1· Cellectar Biosciences, Inc.· Source

• Active, not recruiting

  Remote Monitoring of CGM Data in Pediatric Patients With Newly Diagnosed Type 1 Diabetes (T1D)

  NCT03968055· Stanford University· Source

• Recruiting

  The Myelin Disorders Biorepository Project

  NCT03047369· Children's Hospital of Philadelphia· Source

• Recruiting

  National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

  NCT02852031· Children's Hospital Medical Center, Cincinnati· Source

• Recruiting

  North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

  NCT01694940· Columbia University· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers5 recruiting
• Heart failure5 recruiting
• Congenital heart disease4 recruiting
• Crohn's disease2 recruiting
• Epidermolysis bullosa2 recruiting
• Sickle cell disease2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Cytomegalovirus infection1 recruiting
• Down syndrome1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Haemophilia1 recruiting
• Hearing loss1 recruiting
• High blood pressure1 recruiting
• Insomnia1 recruiting
• Lupus (SLE)1 recruiting
• Mitochondrial disease1 recruiting
• Myasthenia gravis1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Retinitis pigmentosa1 recruiting
• Sarcoma1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

  NCT05627557· Phase 3· Hoffmann-La Roche· Source

• Completed

  Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

  NCT05067634· Phase 3· SK Life Science, Inc.· Source

• Completed

  Teletherapy in Children Who Are Deaf and Hard of Hearing

  NCT04928209· University of California, San Francisco· Source

• Completed

  A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

  NCT03655678· Phase 2/3· Vertex Pharmaceuticals Incorporated· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Congenital heart disease17 works · 4 trials